Abiopharma

🔍 Shafer Andrew (Executive)

Company: Gevo, Inc. (GEVO)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 5,550 shares of Common Stock at $0.71 per share (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 276,373.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,550 shares of Common Stock at $2.2063 per share (Direct)
  Date: 2026-03-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 270,823.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-10 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 16,877.69 | Footnotes: F3
• Acquired 5,550 shares of Stock Option at $0.71 per share (Derivative)
  Date: 2026-03-10 | Code: M | Expires: 2034-05-21 | equity_swap_involved: 0 | shares_owned_after: 196,950.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The reported transactions were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.185 to $2.23 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Between January 25, 2026 and March 10, 2026, the reporting person (i) acquired 7,096.69 shares of the issuer's common stock under the issuer's 401(k) plan; and (ii) disposed of 7.14 shares of the issuer's common stock under the issuer's 401(k) plan to cover administrative fees. The information in this report is based on a plan statement dated February 27, 2026.
• F4: The option became exercisable in three equal annual installments beginning on May 22, 2025.